608 results about "Cell growth" patented technology

The current invention provides a biocompatible energy recharge system to normalize body functions for a mammal. Both stationary and circulatory scalar wave energy was produced and utilized to enable the entire body of a mammal to increase the energy potential of any cell in the body, to promote cell growth, to facilitate cell repair, and to reduce cell destruction, hence the cells, organs, systems and the entire body of a mammal become healthy, and to treat a disease or disorder. The invention is a combination of the generators of the three-dimensional bio-waves in the stationary and in the circulationary formats for empowering the cells in all parts of a mammal, and a method of using the 3D bio-waves uniformly to empower each organ of a mammal to restore and maintain the normal body health and function.

The invention provides a cell growth dynamics prediction method and device based on a space-time image sequence, and belongs to the technical field of computer vision and deep learning. The method comprises the following steps: acquiring a multi-focal-plane space-time image sequence containing a cell complete growth process; preprocessing and normalizing images in the image sequence to obtain a final test image sequence; and inputting the test image sequence into a cell growth dynamics prediction model consisting of a multi-scale feature extraction module and a time sequence modeling module which are connected in sequence to obtain a cell growth stage identification result corresponding to each time point image in the sequence so as to realize cell growth dynamics prediction. The method can effectively solve the problems of poor adaptability, insufficient stability, high labeling cost and the like when a traditional model is used for processing the dynamic medical image sequence, and has remarkable advantages and application prospects in the aspect of dynamic prediction of the cell growth space-time image sequence.

Disclosed in the present invention are a gel having a regulatable free water content and morphology, a preparation method therefor, and the use thereof. The method comprises: S1, preparing a solution A from a natural polymer material; S2, mixing a small molecule material containing a positively charged polar group with the solution A to obtain a composite solution B; S3, mixing the composite solution B with a regulator to obtain a composite solution C, stirring same, then adding a condensing agent to the reaction system, and carrying out a curing crosslinking reaction; and S4, removing the regulator and the condensing agent to obtain the gel. By adjusting the concentrations of the natural polymer material and the regulator, gels having different morphologies can be prepared; the gel undergoes a physical process to remove hydrogen bond interaction between the gel and free water, so that the content of free water attached to the surface of the gel can be regulated, thereby regulating the physical and chemical properties of the gel. The gel of the present invention has regulatable morphology and controllable elastic modulus, and has many advantages such as good lubrication effect, good biocompatibility and biodegradability, capability of being biologically active, and capabilities of stimulating cell growth and accelerating wound repair.

The invention discloses an anisotropic electrostatic spinning patch with ultrasonic response and a preparation method thereof, a fiber membrane with a controllable anisotropic structure is constructed by a biodegradable polymer, antibacterial nanoparticles and a photoinitiator system through a step-by-step directional electrostatic spinning process, so that the mechanical matching property of the fiber membrane is improved; cell growth can be directionally guided and tissue regeneration can be accelerated by combining the piezoelectric material characteristics of the introduced biodegradable polymer with piezoelectric characteristics and electric field stimulation induced by the fiber topological structure; meanwhile, a zwitterionic coating is generated on the surface of the fiber membrane in situ by utilizing a single-sided photocuring technology, and an anti-adhesion function is realized on the single side of the fiber membrane. Furthermore, the soft tissue repair patch which has multiple functions of adjustable mechanical property, infection resistance, adhesion resistance and the like and has better structural mechanical suitability, function integration and tissue regeneration guiding capability is prepared by adopting the anisotropic electrostatic spinning patch with ultrasonic response.

The present invention addresses the problem of providing: synovium-derived mesenchymal stem cells that stably exhibit an excellent therapeutic effect on joint diseases; an arthropathy therapeutic agent that contains the synovium-derived mesenchymal stem cells; a method for producing the synovium-derived mesenchymal stem cells; and a method for selecting synovium-derived mesenchymal stem cells for use as an arthropathy therapeutic agent. The present invention provides synovium-derived mesenchymal stem cells that express at least one of a hepatocyte growth factor, a transforming growth factor β-inducing protein, and tumor necrosis factor superfamily 15.

The invention discloses a field crop growth monitoring method based on low-altitude remote sensing multi-scale data, relates to the technical field of agricultural remote sensing and intelligent monitoring, and is used for solving the problem that a monitoring method integrating multi-scale remote sensing data and having high precision, high adaptability and high efficiency is lacked in the prior art. The method comprises the steps of collecting remote sensing image data of a monitoring area, performing splicing and spectrum correction on images, extracting canopy coverage, vegetation indexes, colors and texture features to construct a feature matrix, and dividing different cells based on clustering analysis; carrying out sampling analysis on the key cells at the middle-distance flight height, further obtaining cell growth vigor characteristics and determining sampling points; single plant growth vigor diagnosis is completed, and a diagnosis result is output; the method can be widely applied to field crop growth monitoring and precision agricultural management work.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The invention discloses a physiological microenvironment-based cell culture simulation system, which relates to the field of cell culture, and comprises a main control unit adopting an embedded microcontroller; the multi-mode environment simulation unit is connected with the main control unit and comprises a fluid shear force module and a mechanical stretching module; the multi-parameter environment monitoring unit is connected with the main control unit and comprises an optical sensor for monitoring cell density, a pH sensor for monitoring environment parameters and a temperature sensor; the culture chamber is used for accommodating a cell culture; the environment regulation and control unit is used for regulating culture environment parameters; the multi-modal environment simulation unit and the multi-parameter environment monitoring unit are integrated, and the main control unit optimizes a multi-target control strategy in a manner of dynamically adjusting a weight coefficient based on cell growth state parameters monitored in real time, so that accurate and adaptive closed-loop management of cell culture is realized.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The invention belongs to the technical field of microorganism application, and particularly relates to a genetically engineered bacterium for producing L-alanine and application of the genetically engineered bacterium in two-stage fermentation of the L-alanine, and the genetically engineered bacterium takes vibrio natrievibrio as a chassis bacterium and can co-express an alanine dehydrogenase gene and an alanine transporter gene. An alanine dehydrogenase gene is heterologously introduced into a vibrio natriticus genome, and an inactivated gene combination with the optimal L-alanine yield is found out by randomly inactivating a key enzyme in a byproduct production pathway, so that the vibrio natriticus genetically engineered bacterium capable of efficiently producing the L-alanine through a fermentation method is constructed. According to the present invention, the L-alanine is produced through the two-stage fermentation by using the gene engineering bacteria through the temperature-sensitive control strategy so as to reduce the influence of the accumulation of the L-alanine on the cell growth, and the high production of the Xiabanmate is provided. The genetically engineered bacterium is short in growth cycle, glucose can be efficiently utilized to convert the genetically engineered bacterium into L-alanine, the L-alanine is transferred to the outside of cells, separation and purification are simple, cell disruption is not needed, and the yield and conversion rate of the L-alanine can both reach a high level.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The application belongs to the technical field of biological medicine, and provides application of an NTSR1 inhibitor in preparation of a drug for enhancing the anti-tumor effect of a PD-1 monoclonal antibody, which is combined application of the NTSR1 inhibitor SR48692 and the PD-1 monoclonal antibody in preparation of a drug for treating lung cancer. The application establishes a subcutaneous lung cancer mouse model and a subcutaneous melanoma mouse model, and evaluates the growth inhibition effect of SR48692 on the two kinds of tumor cancer cells; the result shows that the NTSR1 inhibitor SR48692 can achieve the purpose of treating lung cancer and melanoma by inhibiting the growth of cancer cells.

The invention discloses a preparation method of a novel composite carbon source. The preparation method comprises the following steps: S1, preparing a solution; s2, preparing a culture medium; s3, extracting a genome; s4, extraction of plasmid DNA (deoxyribonucleic acid); s5, preparation of agarose gel electrophoresis; s6, constructing a linearized vector plasmid; s7, preparing an electrotransfection competent cell; and S8, electric conversion treatment. According to the preparation method of the novel composite carbon source, pfkA and pfkB can be respectively, independently and simultaneously knocked out when the carbon source is prepared by utilizing a gene editing technology, the consumption of a glucosamine precursor 6-fructose phosphate in an EMP pathway can be reduced, more glucose is used for synthesizing a target product, and by optimizing the preparation process of the composite carbon source, the yield of the target product is improved. The shake-flask fermentation yield of the glucosamine can be obviously improved, the conversion rate of the composite carbon source is also improved, and cell growth and synthesis of the target product glucosamine can be reasonably balanced, so that the yield of the glucosamine is improved.

The present application relates to the technical field of medicine (IPC classification A61P31 / 22), and particularly relates to a preparation method and application of a tetrahydroindazole antitumor compound, the preparation method comprising: reacting a compound of formula I with adamantanol to obtain a 4-(4-hydrazone-3,6,6-trimethyl-1-tetrahydroindazole)-2-(4-hydroxycyclohexylamino) benzamide compound, compared with a 4-(4-hydrazone-3,6,6-trimethyl-1-tetrahydroindazole)-2-(4-hydroxycyclohexylamino) benzamide compound in the prior art, the compound has stronger inhibition of tumor cell growth activity, has generally lower IC50 values, and in particular can significantly reduce the clonogenicity of non-small cell lung cancer at a low concentration, and causes apoptosis of non-small cell lung cancer cells, and has great significance for development of a novel antitumor drug.

The application discloses a kind of live cell dynamic monitoring method, comprising the following steps: obtaining the cell scanning picture group that live cell grown in culture vessel is photographed under specified condition, and the picture is preprocessed;Cell scanning picture group after pre-processing is input into trained cell identification model, and output cell growth state chart group;Cell growth state chart group is input into trained survival rate calculation model, and the survival rate of cell in each cell growth state chart is output;The cell survival rate numerical value obtained is drawn into cell survival rate-time curve chart;The cell survival rate-time curve chart generated is combined with nonlinear regression statistical method, and the half inhibitory concentration value of the efficacy of specified parameter calculation is selected.The growth state of cell under specified condition is monitored, and the survival rate of cell and the half inhibitory concentration value of the efficacy are calculated based on these data;It can significantly improve the efficiency and accuracy in the field of drug research and development, drug screening, treatment scheme effect, etc.

To provide a cell proliferation system, proliferation method, control method, and culture medium bag capable of proliferating various adherent cells and suspension cells. [Solution] Cells are grown in a bioreactor and activated by an activator (e.g., a soluble activator complex). The nutrient supply and gas exchange functions of an automated closed cell proliferation system make it possible to seed at, for example, a low seeding density. By manipulating the parameters of the cell growth environment, cells are placed in specific locations within the bioreactor for efficient exchange of nutrients and gases. System parameters are adjusted to shear any cell colonies that may form during the proliferation phase. Metabolic concentrations are controlled to improve cell growth and viability. Cell retention within the bioreactor is controlled. In some embodiments, the cells include T cells. In other embodiments, the cells include a T cell subpopulation, for example, regulatory T cells (Tregs).

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

This invention relates to the fields of microbial genetic engineering and fermentation biomanufacturing technology, specifically disclosing a recombinant Corynebacterium glutamicum with high 5-aminolevulinic acid (ALA) production and its applications. Addressing the problems of existing strains such as crude enzyme activity regulation, inhibited cell growth, the need for external inhibitors, and low yield, this invention uses Corynebacterium glutamicum as a host and removes the gdhA gene without scarring to reduce precursor competitive metabolism. Site-directed mutations of the endogenous hemB gene (S288A, D128E, R231K) are performed to moderately reduce dehydratase activity. A high-expression plasmid pXMJ19-hemA containing the hemA gene from Rhodopsinus capsulatum is constructed and introduced into the modified strain to obtain a recombinant strain with optimized triple metabolism. This strain reduces product degradation without the need for external dehydratase inhibitors, does not affect cell growth, and achieves a yield up to 4.30 times higher than the control after 42 hours of fermentation, with ALA accumulation exceeding 8.9 g / L. The strain exhibits stable characteristics, the process is simple, and it has good industrial application value.

The invention belongs to the technical field of gene engineering, and particularly relates to a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of AML patients and application of ubiquitin specific protease 20 serving as a target spot in treating acute myelogenous leukemia. The invention provides a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of an AML patient and application of ubiquitin specific protease 20 as a target spot in treating acute myelogenous leukemia, USP20 is used as a super enhancer regulation gene, and the progress of the AML is promoted by combining with CTNNB1, ERG, ELF1 and RUNX1. The knock-down of the USP20 can significantly inhibit AML proliferation in vivo and in vitro. The wnt-beta-catenin pathway can be influenced by interfering the expression of the USP20 so as to influence the progress of AML (acute myeloid leukemia). And the inhibition effect of the inhibitor AS1517499 subjected to virtual screening on the growth of the AML cells is superior to that of a commercial inhibitor GSK2643943A of USP20.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS. HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

Systems and methods for encapsulating cells in hydrogel tubes for cell growth within hydrogel tubes are described. In aspects, a system includes a plurality of peristaltic pumps and a plurality of pulse dampeners to provide oscillatory-controlled flow rates of each of a cell solution, a hydrogel solution, and a cross-linking solution to an extruder configured to form hollow hydrogel tubes having suspended biological cells in an interior

The subject matter of this specification can be implemented in, among other things, methods, systems, computer-readable storage medium. A method can include receiving cell growth data with a current cell culture of a cell growth system. The cell growth data includes growth input parameter values indicative of a growth rate of the current cell culture. The method can further include identifying, using a first machine learning model, a prescriptive action to alter a yield of a target product of the current cell culture based on the cell growth data. The prescriptive action modifies a metabolism rate of the current cell culture. The method further includes performing at least one of displaying the identified prescriptive on a graphical user interface (GUI) and / or causing the cell growth system to perform the identified prescriptive action.

The invention provides a cell reaction bag with a double-gas-path ventilation device, the cell reaction bag comprises a reaction bag body, a ventilation device and a stirring device, the ventilation device comprises a ventilation disc, the ventilation disc is provided with a first hole group and a second hole group, and the ventilation disc is internally provided with a first channel and a second channel which are respectively communicated with the first hole group and the second hole group; the bottom of the ventilation disc is provided with a first air inlet and a second air inlet which are communicated with the first channel and the second channel respectively. According to the ventilation device disclosed by the invention, two groups of holes with different sizes and corresponding channels are arranged, so that double-gas-path ventilation is formed, different gases can be respectively introduced, large bubbles are generated on the outer side of the ventilation disc, and micro bubbles are generated on the inner side of the ventilation disc; the gas dissolving efficiency is improved, uniform gas distribution is ensured, and uniform growth of cells is facilitated; different requirements on gases such as oxygen and carbon dioxide in the cell culture process can be accurately controlled, and a more suitable gas environment is provided for cell growth.

The utility model discloses an angle-adjustable rotary tank type mesenchymal stem cell balling device, which relates to the technical field of mesenchymal stem cell balling, is arranged in a temperature control incubator for culturing mesenchymal stem cell balling, and comprises a bottle body for containing mesenchymal stem cells and a container for containing ultrasonic buffer water, the container is fixedly arranged on a horizontal bearing surface in the temperature control incubator, the bottle body is obliquely arranged, the bottom of the bottle body is positioned in the ultrasonic buffer water liquid of the container, the bottle body is driven to move by a driving device fixed on the horizontal bearing surface, and the driving device is configured to enable the bottle body to vibrate back and forth in the container along the horizontal direction and simultaneously drive the bottle body to move back and forth. And the bottle body also rotates around the axial direction of the bottle body. According to the utility model, the culture bottle simultaneously performs compound motion of horizontal oscillation and self rotation, so that the cell growth can be more uniformly stimulated, and the problem of poor balling effect caused by single rotation in the traditional method is solved. Through the movement mode, the cells are distributed more uniformly in the culture solution, and the formed spheres are more consistent in size and higher in quality.

The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a breast cancer or a pancreatic cancer). More specifically, the invention concerns the treatment of patients having cancer for the therapeutic inhibition of cancer cell growth and metastasis with an anti-Cadherin 11 monoclonal antibody with specific monoclonal antibody clones 23C6 or 3H10.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

The invention provides a chip system which comprises a cell growth area, the cell growth area comprises a cell layer and a plurality of first scaffolds, the cell layer is used for generating viruses, and each first scaffold comprises a plurality of hydrogel layers; the multiple hydrogel layers are stacked to form a groove, and pores of the multiple hydrogel layers are sequentially reduced in the direction from the interior to the exterior of the groove; the groove is used for accommodating the cell layer, so that viruses generated by the cell layer penetrate through the multi-layer hydrogel layer. The chip system is helpful for reducing the phenomenon of cell shedding in the virus transfection process, and can improve the efficiency of transfecting viruses by cells.

The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp) / kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.